RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
+8.38%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.6B
AUM Growth
-$143M
(-8.2%)
Cap. Flow
-$243M
Cap. Flow
% of AUM
-15.14%
Top 10 Holdings %
Top 10 Hldgs %
36.09%
Holding
105
New
9
Increased
32
Reduced
29
Closed
12
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$21.5M |
| 2 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$21.2M |
| 3 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$16.8M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$12.6M |
| 5 |
Arcellx
ACLX
|
$12.3M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$105M |
| 2 |
Nuvalent
NUVL
|
$25.5M |
| 3 |
Neurocrine Biosciences
NBIX
|
$23.9M |
| 4 |
Legend Biotech
LEGN
|
$17.4M |
| 5 |
UnitedHealth
UNH
|
$15.6M |
Sector Composition
| 1 | Healthcare | 98.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
101
DELISTED
Inozyme Pharma
INZY
| – | – |
-3,445,299
| Closed | -$3.14M |
|
|
102
Legend Biotech
LEGN
$6.58B
| – | – |
-512,932
| Closed | -$17.4M |
|
103
MacroGenics
MGNX
$130M
| – | – |
-1,145,214
| Closed | -$1.45M |
|
104
Pliant Therapeutics
PLRX
$109M
| – | – |
-589,996
| Closed | -$796K |
|